Novavax Shares Are Rising On Incremental COVID-19 Vaccine Related News

The European Medicines Agency (EMA) has begun evaluating an application for conditional marketing authorization for Novavax Inc's NVAX COVID-19 vaccine.
The protein-based vaccine candidate will be marketed in the European Union under the brand name Nuvaxovid.
Separately, Novavax and Serum Institute of India Pvt. Ltd (SII) announced that the Philippine Food and Drug Administration (FDA) had granted emergency use authorization (EUA) for Novavax's COVID-19 vaccine with Matrix-M adjuvant.
The vaccine will be manufactured and marketed in the Philippines by SII under the brand name Covovax. The Novavax/SII vaccine has recently received EUA in Indonesia.
The companies have also filed for emergency authorization in India and Emergency Use Listing (EUL) with the World Health Organization (WHO).
Related Link: Novavax Concludes Filing For WHO's Emergency Use Listing For COVID-19 Vaccine.
Price Action: NVAX shares are up 10.10% at $187.68 during the market session on the last check Wednesday.